Omega Healthcare (OHI) Q3 2026 Earnings Call Transcript

Omega Healthcare Investors reported Q3 2026 revenue of $341 million, up from $312 million a year earlier, and AFFO of $0.82 per share; it raised full-year AFFO guidance to $3.28–$3.30 per share, lifting the midpoint by $0.05 to $3.29. Leverage fell to a company-low 3.1x, while fixed-charge coverage reached 6.9x; management cited $1.5 billion in year-to-date investments and a $26.1 million annual rent increase from transitioning 32 Florida facilities to PACS. Net income declined to $83 million from $180 million, primarily due to $60 million in transition-related expenses and the absence of a prior-year $28 million asset-sale gain. Management said near-term risk of meaningful new long-term-care regulation appears limited, while acknowledging the potential for the political environment to change longer-term regulatory prospects.

Analysis

OHI’s upside is increasingly tied to execution and capital allocation, not simply contractual rent. Converting leases to RIDEA captures operating upside but also transfers labor, reimbursement, and occupancy volatility onto the landlord; flat reported portfolio occupancy makes same-store performance and facility-level cash conversion more important than headline acquisition yields. The Florida transition is a positive proof point, but its apparent 29% yield should not be extrapolated: the termination payment, rent base, and operator economics make it unlike a repeatable acquisition cap rate. PACS may gain scale in Florida, though any benefit to PACS shareholders depends on facility-level margins and staffing costs—not just the added master-lease footprint.

Over 1–3 months, the key test is whether the newly funded investments and transitions support FAD without further equity issuance eroding per-share gains. The large UK mortgage initially provides contractual income, but conversion to a lease and subsequent rent reset depend on regulatory approvals and operating improvement; UK tax friction also reduces net yield. Over 6–18 months, greater RIDEA exposure could improve growth but make OHI less bond-like and more sensitive to staffing rules, reimbursement policy, and operator execution. Regulatory change appears a longer-dated risk, but election-driven policy shifts could alter the economics of skilled nursing.

Contrarian point: the raised AFFO outlook and balance-sheet strength can mask that investment returns are being supported by bespoke restructurings and access to equity capital. Treat management’s pipeline and operator-reported coverage as claims to verify, not assured earnings. Watch same-store occupancy/EBITDAR, FAD per share after funding costs, revolver usage, and the April 2027 maturity plan. Thesis weakens if guidance is cut, coverage deteriorates, or equity funding grows faster than per-share cash flow.

Key Decisions for Investors

• OHI: constructive, but avoid chasing the guidance raise alone. Hold or build exposure selectively; require Q4 evidence that FAD per share absorbs the new capital deployment and transition benefits after financing and share-count effects.
• Do not treat the PACS transition’s quoted yield as a recurring valuation benchmark. Monitor PACS facility staffing and operating performance; no standalone PACS trade is justified by the footprint expansion without facility-level economics.
• Set an alert for OHI if same-store occupancy or operator EBITDAR coverage rolls over, or if funding the pipeline requires material dilution without corresponding per-share AFFO growth; these would challenge the execution thesis.
• Track regulatory proposals and CMS reimbursement changes through the 2027 policy cycle. A concrete staffing or payment change that raises operators’ costs would warrant reducing OHI exposure, especially as RIDEA share grows.